<DOC>
	<DOCNO>NCT02636322</DOCNO>
	<brief_summary>The goal clinical research study learn combination rituximab , lenalidomide , ibrutinib , give alone standard chemotherapy ( call either `` EPOCH '' - Etoposide , Prednisone , Oncovin [ vincristine ] , Cyclophosphamide , Hydroxydaunorubicin [ doxorubicin ] ; `` R-CHOP '' - Rituximab , Cyclophosphamide , Hydroxydaunorubicin [ doxorubicin ] , Oncovin [ vincristine ] , Prednisone ) , help control diffuse large B cell lymphoma . The safety drug combination also study .</brief_summary>
	<brief_title>Study Rituximab , Lenalidomide , Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Study Drug Administration : Each study cycle 21 day . If find eligible take part study , receive 2 cycle rituximab , ibrutinib , lenalidomide . In cycle , receive rituximab vein 4-6 hour Day 1 . You take ibrutinib ( four [ 4 ] capsule ) mouth 1 time every day . You take lenalidomide mouth 1 time every day Days 1-10 cycle . You take capsule time day , 1 cup ( 8 ounce ) water . You swallow capsule whole ; open , break , chew . At end cycle , bring pill bottle ( ) clinic study staff count number pill , , leftover . After first 2 cycle , begin receive either EPOCH R-CHOP . The doctor decide standard treatment receive , base he/she think best interest . If receive EPOCH , cycle , continue receive rituximab , ibrutinib , lenalidomide describe , well : - Etoposide vein 24 hour Days 1-4 cycle . - Prednisone mouth 1 time day Days 1-5 cycle . - Oncovin ( vincristine ) vein 24 hour Days 1-4 cycle . - Cyclophosphamide vein 1 hour Day 5 cycle . - Hydroxydaunorubicin ( doxorubicin ) vein 24 hour Days 1-4 cycle . If receive R-CHOP , cycle , continue receive rituximab , ibrutinib , lenalidomide describe , well : - Cyclophosphamide vein 1 hour Day 1 cycle . - Doxorubicin vein 1 hour Day 1 cycle . - Vincristine vein 1 hour Day 1 cycle . - Prednisone mouth Days 1-5 cycle . Study Visits : Within 3 day begin cycle : - You physical exam . - Blood ( 3-4 tablespoon ) urine collect routine test . If become pregnant , part sample use pregnancy test . Before Cycles 2 3 , blood ( 2-3 tablespoon ) draw test fungal infection . At end Cycles 2 4 , FDG-PET/CT scan check status disease . This may perform early doctor think best interest . During Cycles 3-8 , blood ( 1 tablespoon ) drawn 2 time every week routine test . Length Treatment : You may receive study drug total 8 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Treatment Visit : Within 3-4 week start last cycle , End-of-Treatment visit . The following test procedure perform : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . - You FDG-PET/CT scan check status disease . - If doctor think need , bone marrow biopsy check status disease . Follow-Up : Every 3 month 1 year End-of-Treatment visit , every 4 month 1 year : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . - You CT scan FDG-PET/CT scan check status disease . This investigational study . Ibrutinib FDA approve commercially available treatment certain type patient ( patient mantle cell lymphoma [ MCL ] chronic lymphocytic leukemia [ CLL ] receive least 1 early therapy , CLL patient certain genetic mutation , patient Waldenstrom 's macroglobulinemia [ WM ] ) . Lenalidomide FDA approve commercially available treatment MCL patient receive 2 therapy , multiple myeloma ( MM ) , myelodysplastic syndrome ( MDS ) . Rituximab FDA approve commercially available treatment non-Hodgkin 's lymphoma certain type leukemia . EPOCH R-CHOP FDA approve commercially available use study . The use drug combination investigational . Up 60 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Histopathologically confirm diagnosis previously untreated DLBCL nonGCB DLBCL subtype . 2 . No prior treatment except prior limitedfield radiotherapy , short course glucocorticoid &lt; /= 25mg daily prednisone equivalent must cease prior day 1 cycle 1 , and/or cyclophosphamide urgent lymphoma relate problem diagnosis ( e.g . epidural cord compression , superior vena cava syndrome ) . 3 . Patient durable power attorney ( DPA ) healthcare must able understand voluntarily sign IRBapproved inform consent form . 4 . Age &gt; /=18 year time signing informed consent . 5 . Patients must bidimensional measurable disease , define radiographically apparent disease long dimension &gt; /= 1.5cm . 6 . Patients performance status &lt; /=3 ( 3 allow decline status deem related lymphoma felt potentially reversible treat physician ) 7 . Serum bilirubin &lt; 1.5x ULN except patient Gilbert 's syndrome define &gt; 80 % unconjugated bilirubin ; AST ( SGOT ) ALT ( SGPT ) &lt; /= 3x ULN &lt; 5x ULN hepatic metastasis present ; ANC &gt; 1000/mm^3 platelet &gt; 100,000/mm^3 unless deem related lymphoma involvement bone marrow felt potentially reversible treat physician . 8 . Renal function assess calculated creatinine clearance : . Calculated creatinine clearance &gt; /=30ml/min CockcroftGault formula . See section , Dosing Regimen , regard lenalidomide dose adjustment calculate creatinine clearance &gt; /=30ml/min &lt; 60ml/min . 9 . Patients must willing receive transfusion blood product . 10 . All study participant must register mandatory Revlimid REMS® program , willing able comply requirement REMS® program . 11 . Women childbearing potential must negative serum ( Betahuman chorionic gonadotropin [ BetahCG ] ) urine pregnancy test screening must adhere scheduled pregnancy test require Revlimid REMS® program . 12 . Women childbearing potential men sexually active woman childbearing potential must practice highly effective method birth control study ( 12 month woman 3 month men ) , consistent local regulation regard use birth control method subject participate clinical study . Men must agree donate sperm 3 month conclusion therapy study . 13 . Able take aspirin ( 81mg ) daily alternative therapy prophylactic anticoagulation . 1 . 1 . Any serious medical condition include limited uncontrolled hypertension , uncontrolled congestive heart failure within past 6 month prior screen ( Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification ) , uncontrolled diabetes mellitus , active/symptomatic coronary artery disease , COPD , LVEF le 40 % , renal failure , active infection , history invasive fungal infection , moderate severe hepatic disease ( Child Pugh Class B C ) , active hemorrhage , laboratory abnormality , psychiatric illness , investigator opinion place patient unacceptable risk would prevent subject signing informed consent form . Patients history cardiac arrhythmia cardiac evaluation clearance . 2 . Pregnant lactating female . 3 . Known hypersensitivity lenalidomide thalidomide , ibrutinib , rituximab , etoposide , vincristine , doxorubicin , cyclophosphamide , prednisone . 4 . Known HIV infection . Patients active hepatitis B infection ( include patient prior hepatitis B vaccination ; positive serum Hepatitis B antibody ) . Known hepatitis C infection allow long active disease clear GI consultation . 5 . All patient central nervous system involvement lymphoma . 6 . Diagnosis prior malignancy within past 2 year exception successfully treat basal cell carcinoma , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . History malignancy allow remission ( include prostate cancer patient remission radiation therapy , surgery brachytherapy ) , actively treat , life expectancy &gt; 3 year . 7 . Significant neuropathy ( Grades 2 Grade 1 pain ) within 14 day prior enrollment 8 . Contraindication require concomitant drug supportive treatment intolerance hydration due preexist pulmonary cardiac impairment include pleural effusion require thoracentesis ascites require paracentesis due lymphoma . 9 . Patients active pulmonary embolism deep vein thrombosis ( diagnose within 30 day study enrollment ) . 10 . Patients severe bradycardia ( heart rate &lt; 40 bpm , hypotension , lightheadedness , syncope ) . 11 . Major surgery within 4 week study entry , wound heal prior surgery trauma . 12 . History stroke intracranial hemorrhage within 6 month prior study entry . 13 . Requires anticoagulation warfarin equivalent vitamin K antagonists . 14 . Requires chronic treatment strong CYP3A inhibitor 15 . Vaccinated live , attenuated vaccine within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>High Risk Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>Imbruvica</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Oncovin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Hydroxydaunorubicin</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
</DOC>